Pricing Log in Create free account
Saturday 17 October 2026 Export ZTS’s income statement to Excel — free account

Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.

79.20 0.78 +0.99%
Market cap
$32.4B
P/E
13.0×
Fwd P/E
12.3×
Dividend yield
2.64%
F-score
7/9
Altman Z
5.73
Beneish M
−2.45
Dividend safety
88/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Zoetis Inc. (ZTS) Gross margin

Alert me on Gross margin

Zoetis Inc.'s gross margin over the twelve months to 30 June 2026 was 71.7%, down 0.2 percentage points from fiscal 2025 (71.8%). Over the past ten years it has ranged from 63.5% (fiscal 2015) to 71.8% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers Specialty & Generic industry median of 53.9% and above the Healthcare sector median of 53.5%.

Gross margin, annual

Embed this chart

Annual newest first

Period Gross margin Change (points)
FY2025 71.8% 1.22
FY2024 70.6% 0.59
FY2023 70.0% 0.40
FY2022 69.6% (0.75)
FY2021 70.4% 1.20
FY2020 69.2% 1.00
FY2019 68.2% 0.99
FY2018 67.2% 0.64
FY2017 66.6% 0.63
FY2016 65.9% 2.39

Quarterly newest first

Period Gross margin Change (points)
Jun 2026 72.7% 1.07
Mar 2026 71.7% 0.93
Dec 2025 70.7% (0.81)
Sep 2025 71.5% (1.62)
42 more quarters

Against its own ten years

Low 63.5% High 71.8%
Ten-year median 69.2%
Current reading's percentile 95

Gross margin against peers

Company Gross margin
NBIX Neurocrine Biosciences, Inc. compare 97.9%
UTHR United Therapeutics Corporation compare 86.1%
ZTS Zoetis Inc. 71.7%
TAK Takeda Pharmaceutical Co. compare 65.9%
HLN Haleon PLC Sponsored ADR compare 62.2%
ELAN Elanco Animal Health Incorporated compare 55.4%
TEVA Teva Pharmaceutical Industries Ltd. compare 52.5%
RDY Dr. Reddy's Laboratories Ltd compare 50.0%
VTRS Viatris Inc. compare 34.8%
Drug Manufacturers Specialty & Generic industry median 53.9%
Healthcare sector median 53.5%
Market median 46.2%

What Gross margin is

Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.

Gross Profit ÷ Revenue

The full definition of Gross margin →

More on ZTS